Amble Health expands access to compounded peptide therapies
Amble Health has introduced six new compounded peptide treatments through its telehealth platform, connecting patients directly with licensed providers and 503A pharmacies.
Telehealth provider Amble Health announced on November 5 the expansion of its service offerings to include six compounded peptide treatments, including BPC-157. The service links patients with medical professionals to assess eligibility and manage prescriptions for medications sourced from U.S.-based 503A compounding pharmacies.
This expansion targets the growing market for compounded medications, which are custom-mixed preparations for patients whose medical needs cannot be met by FDA-approved drugs. By utilizing the 503A pharmacy network, the company aims to streamline the procurement process for patients seeking access to specific peptide protocols.
The use of peptides remains a subject of ongoing regulatory scrutiny within the United States, particularly regarding compounding practices. While these compounds are often utilized for wellness and recovery-focused protocols, patients are expected to consult with licensed providers to determine appropriate clinical applications and safety profiles.
Amble Health operates as a digital healthcare intermediary. The company’s model centralizes the clinical consultation and fulfillment logistics, providing an alternative to traditional brick-and-mortar pharmacy procurement for these specific medication classes.